Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cardiovascular actions of human urotensin II--considerations for hypertension.

Literature DB >> 14985940

Cardiovascular actions of human urotensin II--considerations for hypertension.

Fraser D Russell, Peter Molenaar.

Abstract

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2004 PMID： 14985940 DOI： 10.1007/s00210-004-0876-y

Source DB: PubMed Journal: Naunyn Schmiedebergs Arch Pharmacol ISSN： 0028-1298 Impact factor: 3.000

× No keyword cloud information.

21 in total

1. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey.

Authors: S A Douglas; A C Sulpizio; V Piercy; H M Sarau; R S Ames; N V Aiyar; E H Ohlstein; R N Willette
Journal: Br J Pharmacol Date: 2000-12 Impact factor: 8.739

2. High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man.

Authors: Ian B Wilkinson; Jonathan T Affolter; Sanne L de Haas; M Paola Pellegrini; Judith Boyd; Matthew J Winter; Richard J Balment; David J Webb
Journal: Cardiovasc Res Date: 2002-02-01 Impact factor: 10.787

3. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase.

Authors: V Sauzeau; E Le Mellionnec; J Bertoglio; E Scalbert; P Pacaud; G Loirand
Journal: Circ Res Date: 2001-06-08 Impact factor: 17.367

4. Urotensin II evokes potent vasoconstriction in humans in vivo.

Authors: Felix Böhm; John Pernow
Journal: Br J Pharmacol Date: 2002-01 Impact factor: 8.739

5. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries.

Authors: F E Bottrill; S A Douglas; C R Hiley; R White
Journal: Br J Pharmacol Date: 2000-08 Impact factor: 8.739

6. Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents.

Authors: Valeria Camarda; Anna Rizzi; Girolamo Calò; Gabrielle Gendron; Stephan I Perron; Evi Kostenis; Paolo Zamboni; Francesco Mascoli; Domenico Regoli
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2001-11-20 Impact factor: 3.000

7. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1.

Authors: J J Maguire; R E Kuc; A P Davenport
Journal: Br J Pharmacol Date: 2000-10 Impact factor: 8.739

8. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure.

Authors: Fraser D Russell; Deborah Meyers; Andrew J Galbraith; Nick Bett; Istvan Toth; Philip Kearns; Peter Molenaar
Journal: Am J Physiol Heart Circ Physiol Date: 2003-06-05 Impact factor: 4.733

9. Plasma urotensin II in heart failure.

Authors: A Mark Richards; M Gary Nicholls; John G Lainchbury; Stephen Fisher; Timothy G Yandle
Journal: Lancet Date: 2002-08-17 Impact factor: 79.321

10. Congestive heart failure and expression of myocardial urotensin II.

Authors: Stephen A Douglas; Lara Tayara; Eliot H Ohlstein; Nadine Halawa; Adel Giaid
Journal: Lancet Date: 2002-06-08 Impact factor: 79.321

6 in total

1. Enhancement of vascular smooth muscle cell migration by urotensin II.

Authors: Satoshi Matsusaka; Ichiro Wakabayashi
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2006-08-01 Impact factor: 3.000

2. Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity.

Authors: Wei Song; John McDonald; Valeria Camarda; Girolamo Calo; Remo Guerrini; Erika Marzola; Jonathan P Thompson; David J Rowbotham; David G Lambert
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2006-04-05 Impact factor: 3.000